Virinchi Ltd has revised its audited financial results for the quarter and year ended March 31, 2026, following the identification of discrepancies in its earlier filing. The company submitted the revised XBRL documents to the National Stock Exchange of India on June 29, 2026, to correct specific data points across its standalone and consolidated reports. The restatement addresses errors in earnings per share (EPS) figures, segment reporting details, and profit after tax (PAT) numbers to ensure accuracy and compliance with regulatory standards.

The corrections were necessitated by four primary mistakes identified in the original submission. The standalone report contained incorrect EPS figures for discontinued operations, which were erroneously listed despite the absence of profits from such operations. Additionally, there was a mismatch in the segment details provided in the standalone XBRL file compared to the PDF version of the report. On the consolidated front, the company rectified discrepancies in both the PAT figures and the yearly EPS figures that differed between the XBRL and PDF formats.

Key Corrections Made

The filing outlined the specific areas where the data was rectified to align the XBRL submission with the audited financial statements.

The submission was communicated by K Ravindranath Tagore, Company Secretary of Virinchi Limited, confirming that the revised files have been uploaded for the exchange's information and records.

Virinchi Limited shareholders have approved resolutions to grant loans and conduct material related party transactions (RPTs) through a postal ballot process that concluded on July 14, 2026. The approvals allow the company to provide loans under Section 185 of the Companies Act, 2013, and to proceed with specific transactions involving Virinchi Health Care Private Limited and Vivo Bio Tech Limited. The resolutions were passed with the requisite majority based on the votes cast by public non-institutional shareholders, as promoter and institutional categories recorded zero participation.

The postal ballot notice was dispatched on June 12, 2026, pursuant to Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The remote e-voting facility was provided by Central Depository Services (India) Limited (CDSL) and remained open from June 15, 2026, to July 14, 2026. CS Vinay Babu Gade was appointed as the scrutinizer to oversee the voting process and validate the results.

Voting Results Summary

The voting results indicate that only public non-institutional shareholders participated in the e-voting process. A total of 38,185 shareholders were on record as of June 5, 2026. The table below details the voting outcomes for the three resolutions:

Resolution Details

Item No. 1: Loans under Section 185

The resolution sought approval to give loans under Section 185 of the Companies Act, 2013. A total of 2,809,214 votes were polled. The resolution received 2,537,352 votes in favour and 271,862 votes against, resulting in a 90.32% approval rate from the valid votes cast.

Item No. 2: RPTs with Virinchi Health Care Private Limited

Shareholders approved material related party transactions with M/s. Virinchi Health Care Private Limited. The resolution passed with 2,603,809 votes in favour against 205,405 votes, securing a 92.69% majority.

Item No. 3: RPTs with Vivo Bio Tech Limited

The final resolution concerned material related party transactions with M/s. Vivo Bio Tech Limited. It was approved with 2,559,238 votes in favour and 249,976 votes against, reflecting a 91.10% approval from the participating shareholders. The scrutinizer confirmed that no invalid votes were recorded for any of the resolutions.